VISCHER advised Mosanna Therapeutics AG on the deal.Mosanna Therapeutics AG, a Basel-based biotechnology company developing the advanced small molecule MOS118 (formerly know as AVE0118) for the…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
